FDA clears expanded access program for MS stem cell therapy

Neurogenesis’ NG01 to be available to progressive MS patients

Written by Andrea Lobo, PhD |

An image shows a megaphone and a conversation box with the letters

The FDA's expanded access program allows patients access to experimental treatments outside of clinical trials. (Image by iStock)

  • The U.S. FDA cleared an expanded access program for the experimental stem cell therapy NG01 to treat progressive multiple sclerosis.
  • Progressive forms of multiple sclerosis feature chronic brain inflammation, myelin damage, and worsening disability, with limited treatment options.
  • The program provides investigational stem cell treatment to eligible patients while parallel clinical development continues toward FDA approval.

The U.S. Food and Drug Administration (FDA) has cleared Neurogenesis Bio to provide its experimental stem cell therapy NG01 to people with progressive forms of multiple sclerosis (MS) through an expanded access program (EAP).

The program, which will allow certain patients unable to participate in the company’s clinical trials to receive the investigational treatment, will initially launch at the University of Miami, with additional U.S. sites expected to follow.

The first patient has been screened and was scheduled to undergo bone marrow aspiration, the first step in manufacturing the treatment, this week.

“The FDA’s clearance to proceed is a pivotal step for patients with Progressive MS who have limited treatment options,” Guy Bar-Klein, PhD, Neurogenesis’ senior vice president of clinical and strategy, said in a company press release. “Expanded access allows us to responsibly extend NG01 to patients outside of our trials while we continue to advance the program toward approval.”

Recommended Reading
Main banner for Desiree Lama's column,

Learning to listen as I wage a never-ending, silent battle with chronic pain

Family fund helps support program

The EAP is supported in part by a $500,000 gift from the Mendoza Family Fund, created in partnership with the National MS Society. It will run in parallel with NG01’s clinical development, including a planned Phase 2b trial (NCT06961383) expected to start in the first half of next year.

“The generosity of the Mendoza family and the support of the University of Miami embody the kind of collaboration between science, medicine, and community that makes access to an investigational therapy possible for the people who need it most,” said Tal Gilat, Neurogenesis’ CEO.

MS occurs when the immune system mistakenly attacks myelin (the protective covering around nerve fibers) in the brain and spinal cord. This causes damage to nerve cells and disrupts the transmission of nerve signals, leading to a range of MS symptoms.

While treatments can ease acute inflammatory attacks, disability worsening in progressive forms of MS is believed to be mostly driven by chronic inflammatory processes inside the brain. These are not adequately controlled with treatment, and there are no therapies that can effectively promote myelin repair.

NG01 is administered directly into the cerebrospinal fluid (the fluid surrounding the brain and spinal cord). It is designed to reduce inflammation in the brain, protect nerve cells, and stimulate the recruitment of oligodendrocytes, the cells responsible for producing myelin in the brain and spinal cord.

An autologous stem cell therapy, NG01 is manufactured using a patient’s own cells. It involves collecting mesenchymal stem cells (MSCs) — cells able to grow into fat and connective tissue cells and also secrete signaling molecules that coordinate other cells’ activity — from the bone marrow. NG01 is made of a specific population of MSCs that has anti-inflammatory and nerve-protective properties.

After collection and expansion, the cells are returned to the patient through injection into the spinal canal, where they are expected to reach areas of local inflammation that contribute to ongoing nerve damage.

“NG01 takes a different approach from the therapies available to us today,” said Flavia Nelson, a neurologist at the University of Miami who is leading the EAP alongside Denise Pereira, MD, associate director for clinical operations at the University of Miami’s Sylvester Comprehensive Cancer Center. “It is a cell therapy that is designed to act at the affected areas in the brain and spinal cord … which is precisely the biology that drives disability in progressive disease.”

Nelson will also serve as lead principal investigator of the planned Phase 2b trial.

NG01 was evaluated in four completed studies, including a Phase 2 trial (NCT02166021) involving 48 people with progressive forms of MS: 41 with secondary progressive MS (SPMS) and seven with primary progressive MS (PPMS).

The trial compared NG01 delivered into the spinal canal or into the bloodstream against a placebo. Results showed that patients given NG-01 were less likely to have disability progression, although the intrathecal (into the spinal canal) route resulted in greater benefits in a number of outcomes over the intravenous one.

A subsequent biomarker analysis also found reductions in neurofilament light chain (NfL), a biomarker of nerve cell damage, among participants receiving intrathecal treatment. These changes were not observed to the same extent in the other treatment groups.

Based on the findings, NG01 received FDA Regenerative Medicine Advanced Therapy designation earlier this year for the treatment of SPMS. The designation aims to accelerate the development and review of promising regenerative medicine therapies for serious or life-threatening diseases.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.